Nicholas A Zorko (Nicholas Zorko)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 18

Top Topics

Squamous Cell Carcinoma

Radical Prostatectomy

Top Venues

Prostate cancer and prostatic diseases

Current oncology (Toronto, Ont.)

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Carly D Miller, John R Lozada, Nicholas A Zorko, Andrew Elliott, Allison Makovec, Milan Radovich, Elisabeth I Heath, Archana M Agarwal, Rana R McKay, Rohan Garje, Bruno R Bastos, Dave S B Hoon, Jacob J Orme, A Oliver Sartor, Ari M VanderWalde, Chadi Nabhan, George W Sledge, Eugene Shenderov, Scott M Dehm, Emil Lou, Jeffrey S Miller, Justin H Hwang, Emmanuel S Antonarakis
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies. Cancer research communications 4 (5) (2024)
Andrea K Miyahira, Sophia C Kamran, Tamara Jamaspishvili, Catherine Handy Marshall, Kara N Maxwell, Abhijit Parolia, Nicholas A Zorko, Kenneth J Pienta, Howard R Soule
Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey-Holden Prostate Cancer Academy Meeting. The Prostate 84 (11) (2024)
Andrea K Miyahira, Sophia C Kamran, Tamara Jamaspishvili, Catherine Handy Marshall, Kara N Maxwell, Abhijit Parolia, Nicholas A Zorko, Kenneth J Pienta, Howard R Soule
Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey-Holden Prostate Cancer Academy Meeting. The Prostate 84 (11) (2024)
Carly D Miller, John R Lozada, Nicholas A Zorko, Andrew Elliott, Allison Makovec, Milan Radovich, Elisabeth I Heath, Archana M Agarwal, Rana R McKay, Rohan Garje, Bruno R Bastos, Dave S B Hoon, Jacob J Orme, A Oliver Sartor, Ari M VanderWalde, Chadi Nabhan, George W Sledge, Eugene Shenderov, Scott M Dehm, Emil Lou, Jeffrey S Miller, Justin H Hwang, Emmanuel S Antonarakis
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target across Human Malignancies. Cancer research communications (2024)
Nicholas A Zorko, Allison Makovec, Andrew Elliott, Samuel Kellen, John R Lozada, Ali T Arafa, Martin Felices, Madison Shackelford, Pedro Barata, Yousef Zakharia, Vivek Narayan, Mark N Stein, Kevin K Zarrabi, Akash Patniak, Mehmet A Bilen, Milan Radovich, George Sledge, Wafik S El-Deiry, Elisabeth I Heath, Dave S B Hoon, Chadi Nabhan, Jeffrey S Miller, Justin H Hwang, Emmanuel S Antonarakis
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes. Prostate cancer and prostatic diseases (2024)
Nicholas A Zorko, Allison Makovec, Andrew Elliott, Samuel Kellen, John R Lozada, Ali T Arafa, Martin Felices, Madison Shackelford, Pedro Barata, Yousef Zakharia, Vivek Narayan, Mark N Stein, Kevin K Zarrabi, Akash Patniak, Mehmet A Bilen, Milan Radovich, George Sledge, Wafik S El-Deiry, Elisabeth I Heath, Dave S B Hoon, Chadi Nabhan, Jeffrey S Miller, Justin H Hwang, Emmanuel S Antonarakis
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes. Prostate cancer and prostatic diseases (2024)
Nicholas A Zorko, Allison Makovec, Andrew Elliott, Samuel Kellen, John R Lozada, Ali T Arafa, Martin Felices, Madison Shackelford, Pedro Barata, Yousef Zakharia, Vivek Narayan, Mark N Stein, Kevin K Zarrabi, Akash Patniak, Mehmet A Bilen, Milan Radovich, George Sledge, Wafik S El-Deiry, Elisabeth I Heath, Dave S B Hoon, Chadi Nabhan, Jeffrey S Miller, Justin H Hwang, Emmanuel S Antonarakis
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes. Prostate cancer and prostatic diseases (2024)
Carly D Miller, John R Lozada, Nicholas A Zorko, Andrew Elliott, Allison Makovec, Milan Radovich, Elisabeth I Heath, Archana M Agarwal, Rana R McKay, Rohan Garje, Bruno R Bastos, Dave S B Hoon, Jacob J Orme, A Oliver Sartor, Ari M VanderWalde, Chadi Nabhan, George W Sledge, Eugene Shenderov, Scott M Dehm, Emil Lou, Jeffrey S Miller, Justin H Hwang, Emmanuel S Antonarakis
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies. Cancer research communications 4 (5) (2024)
Nicholas A Zorko, Allison Makovec, Andrew Elliott, Samuel Kellen, John R Lozada, Ali T Arafa, Martin Felices, Madison Shackelford, Pedro Barata, Yousef Zakharia, Vivek Narayan, Mark N Stein, Kevin K Zarrabi, Akash Patniak, Mehmet A Bilen, Milan Radovich, George Sledge, Wafik S El-Deiry, Elisabeth I Heath, Dave S B Hoon, Chadi Nabhan, Jeffrey S Miller, Justin H Hwang, Emmanuel S Antonarakis
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes. Prostate cancer and prostatic diseases (2024)
Nicholas A Zorko, Allison Makovec, Andrew Elliott, Samuel Kellen, John R Lozada, Ali T Arafa, Martin Felices, Madison Shackelford, Pedro Barata, Yousef Zakharia, Vivek Narayan, Mark N Stein, Kevin K Zarrabi, Akash Patniak, Mehmet A Bilen, Milan Radovich, George Sledge, Wafik S El-Deiry, Elisabeth I Heath, Dave S B Hoon, Chadi Nabhan, Jeffrey S Miller, Justin H Hwang, Emmanuel S Antonarakis
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes. Prostate cancer and prostatic diseases (2024)
Andrea K Miyahira, Sophia C Kamran, Tamara Jamaspishvili, Catherine Handy Marshall, Kara N Maxwell, Abhijit Parolia, Nicholas A Zorko, Kenneth J Pienta, Howard R Soule
Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey-Holden Prostate Cancer Academy Meeting. The Prostate (2024)
Sree M Lanka, Nicholas A Zorko, Emmanuel S Antonarakis, Pedro C Barata
Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond. Current oncology (Toronto, Ont.) 30 (4) (2023)
Sree M Lanka, Nicholas A Zorko, Emmanuel S Antonarakis, Pedro C Barata
Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond. Current oncology (Toronto, Ont.) 30 (4) (2023)
Sree M Lanka, Nicholas A Zorko, Emmanuel S Antonarakis, Pedro C Barata
Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond. Current oncology (Toronto, Ont.) 30 (4) (2023)
Sree M Lanka, Nicholas A Zorko, Emmanuel S Antonarakis, Pedro C Barata
Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond. Current oncology (Toronto, Ont.) 30 (4) (2023)
Ali T Arafa, Leah R Blader, Karan Ramakrishna, Jeff Engle, Charles J Ryan, Nicholas A Zorko, Gautam Jha, Emmanuel S Antonarakis
Clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case-control study. The Prostate (2023)
Xiaolei Shi, Abderrahman Day, Hannah E Bergom, Sydney Tape, Sylvan C Baca, Zoi E Sychev, Gabrianne Larson, Asha Bozicevich, Justin M Drake, Nicholas A Zorko, Jinhua Wang, Charles J Ryan, Emmanuel S Antonarakis, Justin H Hwang
Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer. NPJ precision oncology 6 (1) (2022)
Nicholas A Zorko, Charles J Ryan
Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs? Prostate cancer and prostatic diseases 24 (4) (2021)